Angion Biomedica Corp

BostonCondos.com is a leading MLS real estate listing database in Boston, MA, offering a comprehensive collection of condos and apartments for sale or rent. With a user-friendly interface, BostonCondos.com simplifies the search process, making it easy for individuals to find their ideal living space in the bustling city of Boston. Generated from their website's infomation

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.

Celyad Oncology is an innovative biotechnology company based in Boston, MA, focused on the discovery and development of advanced technologies for chimeric antigen receptor (CAR) T-cells. The company's mission is to broaden the range of cancer treatment options and address the limitations of current CAR T-cell therapies through a differentiated strategy involving technology platforms and CAR T-cell candidates. With a commitment to scientific excellence, Celyad Oncology publishes its research findings and engages in strategic partnerships to enhance its impact on cancer treatment. The company's recent advancements include the development of its miRNA-based shRNA platform, which has shown promising results in preclinical and clinical trials. Generated from the website